13F Pro Quality Score

26.5/100

Rank #2,574 of 2,884 stocks

View Technology peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

3.1/100

Profitability

55.7/100

Balance Sheet

94.5/100

Earnings Quality

1.2/100

Free Cash Flow

12.9/100

Institutional Flow

21.2/100

Revenue Scale

12.2/100

Dilution Risk

33.1/100
Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

SONM Stock Analysis & AI Quality Score

Data updated 2026-08-18

AI stock analysis and institutional research for DNA X, Inc. (SONM), a Technology sector company. 13F Pro's AI-powered ranking engine scores SONM at 26.5/100 on a 32-signal composite quality model, placing it at rank #2,574 of 2,884 stocks — the bottom half of the AI-ranked universe. SONM scores in the top quartile across balance sheet strength (94.5). Areas of concern include earnings quality (1.2) and revenue growth (3.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 33.1/100, reflecting ongoing share issuance or stock-based compensation. Top institutional holders of SONM by reported 13-F value include C2C Wealth Management, BlackRock, CITADEL ADVISORS, based on the most recent SEC filings. SONM trades on the Nasdaq exchange and files with the SEC under CIK 1178697. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SONM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for DNA X, Inc. directly from SEC EDGAR.

Net Income

Q2 2026

$-1.2M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

FY 2025
FY22 $69.8MFY23 $93.6MFY24 $58.3MFY25

Net Income

+38.6% YoY
$-20.7MFY 2025
FY22 $-14.1MFY23 $-90.0KFY24 $-33.6MFY25 $-20.7M

Operating Income

-74.4% YoY
$-5.4MFY 2025
FY22 $-14.3MFY23 $513.0KFY24 $-3.1MFY25 $-5.4M

EPS (Diluted)

+77.7% YoY
$-28.58FY 2025
FY22 $-0.49FY23 $-0.02FY24 $-128.37FY25 $-28.58

Total Assets

+10.5% YoY
$43.9MFY 2025
FY22 $53.7MFY23 $56.0MFY24 $39.7MFY25 $43.9M

Total Debt

$10.1MFY 2025
FY22 $147.0KFY23 FY24 FY25 $10.1M

Op. Cash Flow

-177.2% YoY
$-23.5MFY 2025
FY22 $-12.4MFY23 $-4.1MFY24 $-8.5MFY25 $-23.5M

Free Cash Flow

FY 2025
FY22 $-12.4MFY23 $-4.1MFY24 $-8.7MFY25

Get alerted when SONM's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for DNA X, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Put SONM on your watchlist

Track score changes the day DNA X, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is SONM a good stock to buy?

13F Pro's AI-powered analysis of DNA X, Inc. (SONM) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Technology sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SONM are available on the SONM stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. SONM is classified as a small company.

Which hedge funds own SONM?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SONM. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of DNA X, Inc.'s investment landscape.